Index -
P/E -
EPS (ttm) -1.46
Insider Own 3.09%
Shs Outstand 191.38M
Perf Week 18.94%
Market Cap 288.28M
Forward P/E -
EPS next Y -0.71
Insider Trans -1.28%
Shs Float 177.94M
Perf Month 18.94%
Income -276.06M
PEG -
EPS next Q -0.19
Inst Own 62.87%
Short Float 1.75%
Perf Quarter 182.88%
Sales 90.12M
P/S 3.20
EPS this Y 38.97%
Inst Trans -4.28%
Short Ratio 1.19
Perf Half Y 223.71%
Book/sh 0.68
P/B 2.29
EPS next Y 19.49%
ROA -49.80%
Short Interest 3.11M
Perf Year 96.15%
Cash/sh 1.65
P/C 0.95
EPS next 5Y -7.30%
ROE -110.95%
52W Range 0.41 - 1.79
Perf YTD 177.88%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -80.69%
52W High -12.29%
Beta 0.73
Dividend TTM -
Quick Ratio 6.14
Sales past 5Y -20.42%
Gross Margin 62.53%
52W Low 280.51%
ATR (14) 0.15
Dividend Ex-Date -
Current Ratio 6.45
EPS Y/Y TTM 26.08%
Oper. Margin -150.05%
RSI (14) 62.34
Volatility 12.19% 12.02%
Employees 137
Debt/Eq 1.76
Sales Y/Y TTM -2.10%
Profit Margin -306.31%
Recom 3.00
Target Price 3.00
Option/Short Yes / Yes
LT Debt/Eq 1.61
EPS Q/Q 30.53%
Payout -
Rel Volume 0.44
Prev Close 1.67
Sales Surprise 11.47%
EPS Surprise -4.56%
Sales Q/Q 8.45%
Earnings May 09 AMC
Avg Volume 2.61M
Price 1.57
SMA20 10.45%
SMA50 44.02%
SMA200 122.32%
Trades
Volume 1,140,403
Change -5.99%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed
JP Morgan
Underweight
Nov-09-23 Upgrade
TD Cowen
Market Perform → Outperform
May-10-23 Upgrade
Jefferies
Underperform → Hold
$1.50 → $1
Feb-24-23 Downgrade
Jefferies
Hold → Underperform
$3.20 → $1.50
Aug-08-22 Downgrade
JP Morgan
Neutral → Underweight
May-31-22 Resumed
Jefferies
Hold
$12 → $4
Apr-18-22 Downgrade
Goldman
Neutral → Sell
$3
Mar-15-22 Downgrade
Mizuho
Buy → Neutral
$35 → $8
Mar-15-22 Downgrade
Cowen
Outperform → Market Perform
Mar-14-22 Downgrade
William Blair
Outperform → Mkt Perform
Mar-14-22 Downgrade
Stifel
Buy → Hold
$24 → $5
Mar-14-22 Downgrade
BTIG Research
Buy → Neutral
Mar-14-22 Downgrade
BofA Securities
Neutral → Underperform
$18 → $6
Mar-09-22 Upgrade
Oppenheimer
Perform → Outperform
$21
Nov-08-21 Upgrade
The Benchmark Company
Hold → Buy
$20
Sep-10-21 Initiated
BofA Securities
Neutral
$18
Jun-28-21 Upgrade
Stifel
Hold → Buy
$22 → $24
May-18-21 Resumed
Goldman
Neutral
$24
Feb-22-21 Downgrade
The Benchmark Company
Buy → Hold
Jan-06-21 Initiated
Stifel
Hold
$18
Show Previous Ratings
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
10:07AM
Loading…
Mar-05-24 10:07AM
09:13AM
09:00AM
07:19AM
(Thomson Reuters StreetEvents)
Mar-04-24 05:30PM
04:51PM
04:42PM
(Associated Press Finance)
04:15PM
08:30AM
Feb-27-24 06:00PM
06:00PM
Loading…
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
(Associated Press Finance)
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Oct-13-23 08:30AM
Oct-02-23 09:00AM
Sep-27-23 09:00AM
07:54AM
Loading…
Sep-14-23 07:54AM
Sep-13-23 09:00AM
Sep-07-23 11:31AM
Sep-06-23 06:00PM
Aug-17-23 07:02PM
Aug-09-23 09:25AM
Aug-08-23 05:30PM
04:23PM
04:15PM
11:08AM
(American City Business Journals)
Aug-07-23 10:23AM
06:30AM
Aug-01-23 06:00PM
Jul-24-23 03:48AM
Jul-16-23 08:49AM
Jun-12-23 06:00PM
Jun-08-23 12:55PM
11:31AM
May-10-23 11:28AM
09:16AM
May-09-23 06:45PM
05:41PM
04:15PM
May-08-23 09:29AM
May-04-23 10:00AM
May-02-23 10:01AM
Apr-27-23 08:30AM
Apr-19-23 08:38AM
Apr-17-23 05:00PM
Apr-16-23 06:30AM
Apr-13-23 10:59AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-02-23 08:27AM
Mar-30-23 11:30AM
Mar-29-23 05:44PM
Mar-24-23 12:00PM
Mar-22-23 09:35AM
Mar-14-23 03:43AM
Feb-28-23 05:15PM
Feb-24-23 10:23AM
07:29AM
Feb-23-23 06:20PM
05:24PM
04:30PM
Jan-09-23 09:04AM
Jan-04-23 09:00AM
Dec-12-22 10:05AM
Dec-05-22 08:00AM
Nov-10-22 09:05AM
07:58AM
Nov-09-22 09:00AM
Nov-04-22 12:35PM
Nov-03-22 06:35PM
Oct-28-22 10:00AM
Oct-27-22 10:02AM
Oct-25-22 06:00PM
Oct-24-22 07:55AM
Oct-11-22 05:13PM
(American City Business Journals)
Oct-07-22 03:42PM
(American City Business Journals)
11:21AM
Sep-07-22 01:15AM
Aug-21-22 09:57AM
Aug-16-22 08:30AM
Aug-05-22 12:11PM
Aug-04-22 06:15PM
04:15PM
Jul-26-22 06:00PM
Jul-14-22 06:01AM
Jul-01-22 06:30AM
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBIN HOWARD W President & CEO Feb 20 '24 Sale 0.68 20,033 13,622 879,889 Feb 22 08:16 PM Zalevsky Jonathan Chief R&D Officer Feb 20 '24 Sale 0.68 9,014 6,130 265,025 Feb 22 08:19 PM Wilson Mark Andrew Chief Legal Officer Feb 20 '24 Sale 0.68 7,606 5,172 236,674 Feb 22 08:17 PM ROBIN HOWARD W President & CEO Nov 17 '23 Sale 0.49 19,877 9,740 899,922 Nov 20 08:58 PM Zalevsky Jonathan Chief R&D Officer Nov 17 '23 Sale 0.49 9,646 4,727 274,039 Nov 20 09:02 PM Wilson Mark Andrew Chief Legal Officer Nov 17 '23 Sale 0.49 7,179 3,518 243,780 Nov 20 09:00 PM Curet Myriam Director Sep 18 '23 Sale 0.69 4,359 3,008 27,418 Sep 20 08:09 PM Ajer Jeffrey Robert Director Sep 18 '23 Sale 0.69 4,359 3,008 34,153 Sep 20 08:06 PM ROBIN HOWARD W President & CEO Aug 16 '23 Sale 0.78 19,998 15,598 919,799 Aug 17 08:06 PM Zalevsky Jonathan Chief R&D Officer Aug 16 '23 Sale 0.78 9,703 7,568 283,685 Aug 17 08:08 PM Wilson Mark Andrew Chief Legal Officer Aug 16 '23 Sale 0.78 7,221 5,632 250,959 Aug 17 08:07 PM WHITFIELD ROY A Director Jun 14 '23 Sale 0.57 30,000 17,100 216,250 Jun 15 06:26 PM ROBIN HOWARD W President & CEO May 16 '23 Sale 0.72 20,361 14,660 939,797 May 17 08:27 PM Zalevsky Jonathan Chief R&D Officer May 16 '23 Sale 0.72 9,791 7,050 293,388 May 17 08:29 PM Wilson Mark Andrew Chief Legal Officer May 16 '23 Sale 0.72 7,543 5,431 257,680 May 17 08:28 PM
Index -
P/E -
EPS (ttm) -1.11
Insider Own 23.13%
Shs Outstand 36.83M
Perf Week 24.44%
Market Cap 132.83M
Forward P/E -
EPS next Y -0.85
Insider Trans 82.45%
Shs Float 30.85M
Perf Month 43.29%
Income -56.83M
PEG -
EPS next Q -0.30
Inst Own 56.21%
Short Float 0.79%
Perf Quarter 215.24%
Sales 0.00M
P/S -
EPS this Y -10.89%
Inst Trans -0.33%
Short Ratio 0.72
Perf Half Y 222.93%
Book/sh 2.31
P/B 1.43
EPS next Y 24.49%
ROA -45.04%
Short Interest 0.24M
Perf Year 53.95%
Cash/sh 2.31
P/C 1.43
EPS next 5Y -
ROE -48.79%
52W Range 0.72 - 3.69
Perf YTD 233.50%
Dividend Est. -
P/FCF -
EPS past 5Y 48.08%
ROI -60.65%
52W High -10.30%
Beta 1.22
Dividend TTM -
Quick Ratio 12.00
Sales past 5Y 0.00%
Gross Margin -
52W Low 359.72%
ATR (14) 0.32
Dividend Ex-Date -
Current Ratio 12.00
EPS Y/Y TTM 21.54%
Oper. Margin 0.00%
RSI (14) 64.31
Volatility 9.91% 12.03%
Employees 51
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 9.67
Option/Short No / Yes
LT Debt/Eq 0.02
EPS Q/Q -2.62%
Payout -
Rel Volume 1.00
Prev Close 2.97
Sales Surprise -
EPS Surprise 10.98%
Sales Q/Q -
Earnings Feb 13 AMC
Avg Volume 336.17K
Price 3.31
SMA20 15.88%
SMA50 43.61%
SMA200 127.10%
Trades
Volume 335,677
Change 11.45%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-09-24 Initiated
Maxim Group
Buy
$8
Aug-02-22 Resumed
Canaccord Genuity
Buy
$17
Jun-15-22 Initiated
Cantor Fitzgerald
Overweight
$9
Sep-08-21 Initiated
ROTH Capital
Buy
$21
May-27-21 Initiated
Oppenheimer
Outperform
$25
May-25-21 Initiated
H.C. Wainwright
Buy
$21
Apr-23-24 08:00AM
Mar-20-24 02:33PM
Mar-06-24 07:30AM
Feb-13-24 04:05PM
Jan-24-24 08:00AM
08:00AM
Loading…
Jan-23-24 08:00AM
Dec-14-23 08:00AM
Dec-13-23 08:00AM
Nov-24-23 11:14AM
Nov-17-23 08:00AM
Nov-13-23 04:05PM
Oct-17-23 08:00AM
Oct-11-23 08:00AM
Sep-14-23 04:05PM
Sep-06-23 07:00AM
04:05PM
Loading…
Jun-27-23 04:05PM
Jun-01-23 12:45PM
May-11-23 04:05PM
Mar-23-23 04:50PM
Mar-08-23 07:00AM
Feb-10-23 04:05PM
Dec-15-22 07:00AM
Nov-09-22 04:05PM
Nov-01-22 07:00AM
Oct-20-22 07:00AM
Sep-15-22 04:05PM
Sep-07-22 07:00AM
Aug-15-22 08:36AM
Jun-01-22 07:00AM
May-12-22 04:05PM
04:01PM
Loading…
May-04-22 04:01PM
09:33AM
May-01-22 11:25PM
02:00PM
Apr-26-22 04:05PM
Mar-29-22 07:00AM
Mar-23-22 07:00AM
Feb-22-22 07:00AM
Feb-09-22 04:05PM
Nov-12-21 04:05PM
Oct-19-21 12:14PM
Oct-13-21 08:10AM
Oct-12-21 04:05PM
Sep-22-21 04:05PM
Sep-15-21 04:56PM
Sep-09-21 04:05PM
Sep-07-21 04:05PM
Aug-10-21 07:00AM
Aug-03-21 07:00AM
Jun-28-21 07:00AM
Jun-24-21 09:01PM
Jun-03-21 05:35AM
May-31-21 10:17AM
May-27-21 07:00AM
May-20-21 07:00AM
May-18-21 07:00AM
May-17-21 04:05PM
07:00AM
May-04-21 08:00AM
Apr-19-21 08:00AM
Mar-22-21 08:00AM
Mar-08-21 08:00AM
Mar-02-21 05:16PM
Feb-10-21 04:05PM
Jan-12-21 08:30AM
Jan-11-21 07:56AM
Dec-28-20 04:05PM
Dec-03-20 08:00AM
Nov-19-20 08:00AM
Nov-05-20 08:00AM
Oct-09-20 08:30AM
Sep-10-20 08:00AM
Jul-27-20 08:00AM
Jun-15-20 08:30AM
May-28-20 08:30AM
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ROBERTS BRIAN KENNETH Chief Medical Officer Mar 28 '24 Buy 2.55 500 1,275 1,076 Mar 29 11:08 AM Evans Daron CFO Mar 15 '24 Buy 1.69 20,000 33,830 20,000 Mar 19 09:17 AM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 14 '24 Buy 1.88 10,000 18,800 10,000 Mar 18 11:20 AM Evans Daron CFO Mar 08 '24 Buy 1.93 50,000 96,345 120,900 Mar 08 12:37 PM Kim Young-Jin Director Mar 07 '24 Buy 1.91 36,503 69,859 115,450 Mar 14 10:35 AM ROBERTS BRIAN KENNETH Chief Medical Officer Mar 07 '24 Buy 1.85 500 925 500 Mar 11 10:35 AM Elam Nevan C CEO Feb 26 '24 Buy 1.68 5,000 8,400 7,817 Feb 28 11:40 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 26 '24 Buy 1.70 2,000 3,400 42,552 Feb 27 08:47 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 23 '24 Buy 1.69 6,000 10,140 40,552 Feb 27 08:47 AM Evans Daron CFO Feb 16 '24 Buy 1.30 41,900 54,411 70,900 Feb 20 07:01 AM Evans Daron CFO Feb 16 '24 Buy 1.37 9,000 12,330 4,500 Feb 20 07:01 AM ROBERTS BRIAN KENNETH Chief Medical Officer Feb 16 '24 Buy 1.31 7,000 9,142 34,552 Feb 21 11:55 AM ROBERTS BRIAN KENNETH Chief Medical Officer Jul 03 '23 Buy 1.90 5,000 9,500 27,552 Jul 06 11:18 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite